Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma
Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma
复制标题
DOI：
10.1016/j.ejim.2006.02.012
复制
发表时间：
2006-10-01
影响因子：
8
通讯作者：
Stathopoulos, Efstathios N.
中科院分区：
文献类型：
--
作者：
Alexandrakis, Michael G.;Pappa, Constantina A.;Stathopoulos, Efstathios N.
背景：白介素17(IL-17)是一种CD4T细胞来源的血管生成介质，能刺激血管内皮细胞迁移，调节多种促血管生成因子的产生，如肿瘤坏死因子-α(TNF-α)和血管内皮细胞生长因子(VEGF)。方法：检测40例初治多发性骨髓瘤患者血清IL-17、肿瘤坏死因子-α、血管内皮生长因子水平及微血管密度。结果：多发性骨髓瘤患者血清IL-17水平高于正常对照组，但差异无统计学意义。MM患者血清中肿瘤坏死因子-α和血管内皮生长因子水平均显著高于正常对照组(P
Background: Interleukin-17 (IL-17) is a CD4 T-cell-derived mediator of angiogenesis that stimulates vascular endothelial cell migration and regulates the production of a variety of proangiogenic factors, such as tumor necrosis factor-alpha (TNF-alpha) and vascular endothelial cell growth factor (VEGF). Angiogenesis is implicated in the progression of multiple myeloma (MM).Methods: We measured serum levels of IL-17, TNF-alpha, and VEGF, as well as microvessel density (MVD) in 40 untreated MM patients.Results: Levels of IL-17 in the sera of patients with MM were higher than those in matched controls; however, the difference did not reach statistical significance. Serum levels of both TNF-alpha and VEGF in MM patients were significantly higher than those in controls (P